Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection (Q40757127)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 March 2016

Language	Label	Description	Also known as
English	Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection	scientific article published on 10 March 2016

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection (English)

1 reference

Europe PubMed Central

23 September 2017

congenital disorder

0 references

vector-borne disease

0 references

0 references

Cytomegalovirus

0 references

lymphocytic choriomeningitis

1 reference

based on heuristic

inferred from title

Farshad Guirakhoo

8

object named as

Farshad Guirakhoo

1 reference

Europe PubMed Central

23 September 2017

Thomas P. Monath

9

object named as

Thomas Monath

1 reference

Europe PubMed Central

23 September 2017

David I Bernstein

10

object named as

David I Bernstein

1 reference

Europe PubMed Central

23 September 2017

author name string

Rhonda D Cardin

1

1 reference

Europe PubMed Central

23 September 2017

Fernando J Bravo

2

1 reference

Europe PubMed Central

23 September 2017

Derek A Pullum

3

1 reference

Europe PubMed Central

23 September 2017

Klaus Orlinger

4

1 reference

Europe PubMed Central

23 September 2017

Elizabeth M Watson

5

1 reference

Europe PubMed Central

23 September 2017

Andreas Aspoeck

6

1 reference

Europe PubMed Central

23 September 2017

Gerhard Fuhrmann

7

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

10 March 2016

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

34

1 reference

Europe PubMed Central

23 September 2017

1993-1999

1 reference

Europe PubMed Central

23 September 2017

17

1 reference

Europe PubMed Central

23 September 2017

Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Ten-year clinical, developmental, and intellectual follow-up of children with congenital cytomegalovirus infection without neurologic symptoms at one year of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Vaccine prevention of maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Kinetics of protective antibodies are determined by the viral surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Experimental Congenital Infection with Cytomegalovirus: A Guinea Pig Model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Comparison of vaccine strategies against congenital CMV infection in the guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection aga

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Insights into viral transmission at the uterine-placental interface.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Cytomegalovirus infection and antibody protection of the developing placenta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.005

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.03.005

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40757127&oldid=2146975541"